Category: Webcast

In this session Far East Gold’s CEO and Director Shane Menere discussed the standout assays from our Woyla drilling campaigns that form the base of our upcoming maiden JORC resource publication.

In this session Prescient CEO and Managing Director Steven Yatomi-Clarke discussed why the data from their PTX-100 Phase 1b trial is so promising.

Join Stuart Roberts, co-founder and senior analyst at Pitt Street Research, for an online briefing where he will outline the recent Pitt Street Research report on Prescient Therapeutics.

In this session Far East Gold’s CEO and Director Shane Menere discussed, why the Board (including Nickel Industries MD Justin Werner) is optimistic about the findings so far……

In this session VP Minerals (VPM) Non-Executive Director Graham Howard discussed VPM’s continued resource inventory targeting high grade critical mineral deposits.

In this session Propell CEO Michael Davidson discussed Propell’s recent progress on the platform, cost base, and establishing a broker network…

In this session Prescient CEO and Managing Director Steven Yatomi-Clarke discussed the new PTX-100 Phase 1b clinical study results, following their unveiling at the American Society of Hematology (ASH) conference.

In this session Wellnex Life MD Zack Bozinovski, CEO George Karafotias and new Board appointment Andrew Vidler discussed how the transformative acquisition of leading topical pain relief brand Pain Away complements Wellnex Life’s position and growth strategy whilst adding immediate scale.

In this session Far East Gold’s Chairman Paul Walker and GM of Exploration Mike Corey discussed the high-grade copper and gold mineralization identified through geological mapping and surface rock sampling at the Sentul and Buluroto prospect areas.

In this session Felix Gold Executive Director Joseph Webb discussed Felix’s prospects in the world-class Alaskan region including high grade critical mineral antimony assays of up to 28% Sb.

Join Stuart Roberts, co-founder and senior analyst at Pitt Street Research, for an online briefing where he will outline the recent Pitt Street Research report on Prescient Therapeutics.

In this session Prescient CEO and Managing Director Steven Yatomi-Clarke provide a company update structured in a Q&A format to field key questions from investors. Steven discussed the key highlights.